Genetic Analysis AS (XSAT:GEAN)

Market Cap	41.67M +59.1%
Revenue (ttm)	20.45M +10.0%
Net Income	-9.20M
EPS	-0.15
Shares Out	69.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,828
Average Volume	29,712
Open	0.7150
Previous Close	0.6750
Day's Range	0.6450 - 0.7150
52-Week Range	0.4480 - 2.6000
Beta	2.30
RSI	37.47
Earnings Date	Feb 27, 2026

About Genetic Analysis AS

Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discovery, a tool to search biomarkers and validate research findings or transfer the findings to a ready-to-use routine testing platform; GA-map Sample Colle...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 16
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: GEAN

Financial Performance

In 2024, Genetic Analysis AS's revenue was 20.68 million, a decrease of -10.71% compared to the previous year's 23.16 million. Losses were -14.77 million, -37.99% less than in 2023.

Financial numbers in NOK